ATOD
MCID: DRM053
MIFTS: 65

Dermatitis, Atopic (ATOD)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dermatitis, Atopic

MalaCards integrated aliases for Dermatitis, Atopic:

Name: Dermatitis, Atopic 57 43 38 71
Atopic Dermatitis 11 42 75 14 31 33
Atopic Eczema 11 42 5 14 16 33
Dermatitis, Atopic, Susceptibility to, 1 57 28
Atopic Neurodermatitis 11
Dermatitis, Atopic, 1 12
Dermatitis, Atopic 1 57
Allergic Dermatitis 11
Besnier's Prurigo 11
Dermatitis Atopic 53
Besnier Prurigo 33
Eczema, Atopic 57
Eczema 71
Atod 57

Characteristics:


Inheritance:

Autosomal dominant 57

OMIM®:

57 (Updated 24-Oct-2022)
Miscellaneous:
food intolerance
diagnosis requires 3 major features (a positive family history is also considered a major feature) and at least 3 minor features


Classifications:



Summaries for Dermatitis, Atopic

MedlinePlus Genetics: 42 Atopic dermatitis (also known as atopic eczema) is a disorder characterized by inflammation of the skin (dermatitis). The condition usually begins in early infancy, and it often disappears before adolescence. However, in some affected individuals the condition continues into adulthood; in others, it does not begin until adulthood. Hallmarks of atopic dermatitis include dry, itchy skin and red rashes that come and go. The rashes can occur on any part of the body, although the pattern tends to be different at different ages. In affected infants, the rashes commonly occur on the face, scalp, hands, and feet. In children, the rashes are usually found in the bend of the elbows and knees and on the front of the neck. In adolescents and adults, the rashes typically occur on the wrists, ankles, and eyelids in addition to the bend of the elbows and knees. Scratching the itchy skin can lead to oozing and crusting of the rashes and thickening and hardening (lichenification) of the skin. The itchiness can be so severe as to disturb sleep and impair a person's quality of life.The word "atopic" indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. Atopic dermatitis is often the beginning of a series of allergic disorders, referred to as the "atopic march." Development of these disorders typically follows a pattern, beginning with atopic dermatitis, followed by food allergies, then hay fever, and finally asthma. However, not all individuals with atopic dermatitis will progress through the atopic march, and not all individuals with one allergic disease will develop others.Individuals with atopic dermatitis have an increased risk of developing other conditions related to inflammation, such as inflammatory bowel disease, rheumatoid arthritis, and hair loss caused by a malfunctioning immune reaction (alopecia areata). They also have an increased risk of having a behavioral or psychiatric disorder, such as attention-deficit/hyperactivity disorder (ADHD) or depression.In a particular subset of individuals with atopic dermatitis, the immune system is unable to protect the body from foreign invaders such as bacteria and fungi (which is known as immunodeficiency). These individuals are prone to recurrent infections. Most also have other allergic disorders, such as asthma, hay fever, and food allergies.Atopic dermatitis can also be a feature of separate disorders that have a number of signs and symptoms, which can include skin abnormalities and immunodeficiency. Some such disorders are Netherton syndrome; immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome; and severe dermatitis, multiple allergies, metabolic wasting (SAM) syndrome.

MalaCards based summary: Dermatitis, Atopic, also known as atopic dermatitis, is related to allergic disease and dermatitis, atopic, 3, and has symptoms including exanthema and pruritus. An important gene associated with Dermatitis, Atopic is FLG (Filaggrin), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and Cytokine Signaling in Immune system. The drugs Zinc oxide and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and breast, and related phenotypes are cataract and ichthyosis

OMIM®: 57 Atopic dermatitis (ATOD), also known as eczema, is a common chronic pruritic inflammatory skin disease with a strong genetic component. Onset typically occurs during the first 2 years of life (review by Soderhall et al., 2007). (603165) (Updated 24-Oct-2022)

Disease Ontology: 11 An allergic contact dermatitis that is a chronically relapsing inflammatory allergic response located in the skin that causes itching and flaking.

Wikipedia: 75 Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin... more...

Related Diseases for Dermatitis, Atopic

Diseases in the Dermatitis, Atopic family:

Dermatitis, Atopic, 2 Dermatitis, Atopic, 3
Dermatitis, Atopic, 4 Dermatitis, Atopic, 5
Dermatitis, Atopic, 6 Dermatitis, Atopic, 7
Dermatitis, Atopic, 8 Dermatitis, Atopic, 9

Diseases related to Dermatitis, Atopic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1142)
# Related Disease Score Top Affiliating Genes
1 allergic disease 33.3 TSLP RNASE3 MIR155 IL5 IL4 IL13
2 dermatitis, atopic, 3 33.2 TSLP ATOD3
3 eczema herpeticum 33.0 TSLP SPINK5 IL4 IL31 IL13 FLG
4 dermatitis, atopic, 5 32.9 TSLP ATOD5
5 egg allergy 32.9 TSLP IL5 IL4 IL13 FLG
6 milk allergy 32.8 TSLP RNASE3 IL5 IL4 IL13
7 allergic asthma 32.7 TSLP RNASE3 IL5 IL4 IL13 IFNG
8 pollen allergy 32.6 IL5 IL4 IL13
9 conjunctivitis 32.5 RNASE3 IL5 IL4 IL13 IFNG
10 hypereosinophilic syndrome 32.4 RNASE3 IL5 IL4 IL13 IFNG CCL17
11 proteasome-associated autoinflammatory syndrome 1 32.2 RNASE3 IL5 IL4 IL13 IFNG
12 alopecia 32.2 IL4 IFNG FLG
13 ichthyosis vulgaris 32.1 TSLP SPINK5 FLG
14 alopecia areata 32.1 IL4 IL13 IFNG FLG
15 viral infectious disease 32.0 MIR155 IL4 IL13 IFNG
16 allergic conjunctivitis 32.0 TSLP RNASE3 IL5 IL4 IL13 IFNG
17 skin atrophy 32.0 IL4 IL31 FLG
18 chronic urticaria 32.0 RNASE3 IL5 IL31
19 respiratory failure 32.0 RNASE3 MIR155 IL5 IL4 IL13 IFNG
20 hyper ige syndrome 31.9 SPINK5 RNASE3 IL4 IFNG
21 chronic spontaneous urticaria 31.9 TSLP IL5 IL4 IL31 IL13
22 dermatitis 31.9 TSLP SPINK5 RNASE3 IL5 IL4 IL31
23 common cold 31.9 TSLP RNASE3 IL5 IL4 IL13
24 primary cutaneous t-cell non-hodgkin lymphoma 31.8 MIR155 IL5 IL4 IFNG CCL17
25 keratoconjunctivitis 31.8 RNASE3 IL5 IL4 IL13 IFNG
26 nasopharyngitis 31.8 IL5 IL31 IL13
27 peanut allergy 31.8 TSLP IL5 IL4 IL13 IFNG FLG
28 esophagitis, eosinophilic, 1 31.8 TSLP SPINK5 RNASE3 IL5 IL4 IL13
29 esophagitis 31.8 TSLP RNASE3 IL5 IL4 IL13 FLG
30 childhood-onset asthma 31.8 TSLP RNASE3 IL5 IL4 IL13 CCL17
31 mycosis fungoides 31.7 MIR155 IL5 IL4 IFNG CCL22 CCL17
32 bronchitis 31.7 RNASE3 IL5 IL4 IL13
33 eosinophilic gastroenteritis 31.7 RNASE3 IL5 IL4 IL13
34 fungal infectious disease 31.7 IL5 IL4 IL13 IFNG
35 celiac disease 1 31.6 TSLP IL5 IL4 IL13 IFNG
36 lichen planus 31.6 IL4 IFNG FLG
37 pemphigoid 31.6 RNASE3 IL5 IL4 IL31 IL13 IFNG
38 tetanus 31.6 IL5 IL4 IL13 IFNG
39 sezary's disease 31.6 MIR155 IL5 IL4 IL31 IFNG CCL17
40 folliculitis 31.6 IL5 IL4 IFNG
41 bullous pemphigoid 31.5 RNASE3 IL5 IL4 CCL17
42 skin disease 31.5 TSLP SPINK5 RNASE3 MIR155 IL5 IL4
43 otitis media 31.5 SPINK5 RNASE3 IL5 IL4 IL13 IFNG
44 parasitic helminthiasis infectious disease 31.4 TSLP RNASE3 IL5 IL4 IL13 IFNG
45 contact dermatitis 31.4 TSLP SPINK5 RNASE3 MIR155 IL5 IL4
46 aspergillosis 31.4 IL5 IL4 IFNG CCL17
47 diphtheria 31.4 IL5 IL4 IL13 IFNG
48 allergic contact dermatitis 31.3 TSLP SPINK5 RNASE3 MIR155 IL5 IL4
49 cow milk allergy 31.3 IL5 IL4 IL13
50 food allergy 31.3 TSLP RNASE3 IL5 IL4 IL13 IFNG

Graphical network of the top 20 diseases related to Dermatitis, Atopic:



Diseases related to Dermatitis, Atopic

Symptoms & Phenotypes for Dermatitis, Atopic

Human phenotypes related to Dermatitis, Atopic:

30 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cataract 30 HP:0000518
2 ichthyosis 30 HP:0008064
3 dry skin 30 HP:0000958
4 pallor 30 HP:0000980
5 asthma 30 HP:0002099
6 conjunctivitis 30 HP:0000509
7 eczema 30 HP:0000964
8 abnormality of metabolism/homeostasis 30 HP:0001939
9 keratoconus 30 HP:0000563
10 pruritus 30 HP:0000989
11 keratosis pilaris 30 HP:0032152
12 recurrent skin infections 30 HP:0001581
13 food intolerance 30 HP:0012537
14 atopic dermatitis 30 HP:0001047
15 infra-orbital fold 30 HP:0011232
16 facial erythema 30 HP:0001041
17 allergic rhinitis 30 HP:0003193
18 flexural lichenification 30 HP:0007453

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Skin Nails Hair Skin:
ichthyosis
keratosis pilaris
facial erythema
palmar hyperlinearity
xerosis
more
Head And Neck Nose:
allergic rhinitis

Immunology:
elevated ige

Head And Neck Eyes:
keratoconus
cataracts (anterior- subcapsular)
conjunctivitis (recurrent)
orbital darkening

Respiratory Airways:
bronchial asthma

Laboratory Abnormalities:
immediate (type i) skin test reactivity

Clinical features from OMIM®:

603165 (Updated 24-Oct-2022)

UMLS symptoms related to Dermatitis, Atopic:


exanthema; pruritus

Drugs & Therapeutics for Dermatitis, Atopic

Drugs for Dermatitis, Atopic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 346)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc oxide Approved Phase 4 1314-13-2
2
Coal tar Approved Phase 4 8007-45-2
3
Omalizumab Approved, Investigational Phase 4 242138-07-4
4
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
5
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
6
Carbamide peroxide Approved Phase 4 124-43-6
7
Desonide Approved, Investigational Phase 4 638-94-8 5311066
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
12
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8 4474933
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
14
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
15
Desoximetasone Approved Phase 4 382-67-2 5311067
16
Montelukast Approved Phase 4 158966-92-8 5281040
17
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
18
Levocetirizine Approved Phase 4 130018-77-8 1549000
19
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Promethazine Approved, Investigational Phase 4 60-87-7 4927
22
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
23
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
24
Dicloxacillin Approved, Investigational, Vet_approved Phase 4 3116-76-5 18381
25
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
26
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
28
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
29
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
30
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
31
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
32
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6509979
33
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
34
Alitretinoin Approved, Investigational Phase 4 5300-03-8 449171
35
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
37
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
38
Cortisone Experimental Phase 4 53-06-5 222786
39
Halometasone Experimental Phase 4 50629-82-8 12811517
40 Ergocalciferols Phase 4
41
Vitamin D2 Phase 4 3249
42 Keratolytic Agents Phase 4
43 glucocorticoids Phase 4
44 Hormones Phase 4
45 Hormone Antagonists Phase 4
46 Histamine H1 Antagonists, Non-Sedating Phase 4
47 Immunoglobulin E Phase 4
48 Acidophilus Phase 4
49 Protective Agents Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show top 50) (show all 1184)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
2 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
3 A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study Unknown status NCT03257215 Phase 4 Stoss vitamin D;Daily vitamin D;Stoss placebo;Daily placebo
4 Effects of Interleukin (IL)-4/IL-13 Blockade on the Structure and Function of Cutaneous Sensory Nerves: An Open-label, Single-arm Longitudinal Study With Dupilumab Unknown status NCT04520308 Phase 4 Dupilumab Only Product
5 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
6 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
7 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
8 Clinical Evaluation of the Effect of Moisturising Cream on Skin Moisture in Atopic Dermatitis Completed NCT00846235 Phase 4
9 A Randomized, Double-Blind, Intra-Individual, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Different Application Rates of Topically Applied Crisaborole Ointment 2% in Adult Subjects With Mild to Moderate Atopic Dermatitis Completed NCT03868098 Phase 4 Crisaborole 2%;Placebo ointment
10 Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis Completed NCT01148667 Phase 4
11 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
12 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
13 Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study Completed NCT01745159 Phase 4 tacrolimus
14 Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to Severe Atopic Dermatitis Completed NCT04447417 Phase 4 Dupilumab SAR231893
15 A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis Completed NCT04823130 Phase 4 Dupilumab SAR231893
16 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
17 Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
18 Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis Completed NCT02680301 Phase 4 0.1% triamcinolone CREAM;0.1% triamcinolone OINTMENT
19 Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life: an Observational Study Completed NCT04900948 Phase 4 Pimecrolimus cream 1%;cream 0.1% methylprednisolone aceponate
20 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
21 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
22 Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
23 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
24 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus
25 A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) Completed NCT04033367 Phase 4 DUPILUMAB;PLACEBO
26 An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis Completed NCT01093469 Phase 4 Atopiclair Nonsteroidal Cream;EpiCeram
27 Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study Completed NCT01065714 Phase 4 Hydrogel vehicle;Eucerin Lotion
28 Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
29 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
30 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
31 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
32 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
33 Short Term Growth in Children With Atopic Dermatitis Completed NCT00236106 Phase 4 tacrolimus ointment 0.1%;mometasone furoate 0.1%
34 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
35 An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD) Completed NCT00119158 Phase 4 Combination of pimecrolimus and fluticasone;pimecrolimus
36 A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS Completed NCT03356977 Phase 4 Crisaborole ointment 2%
37 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4 Investigational OTC Cream;0.05% Desonide Cream
38 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis Completed NCT01077882 Phase 4
39 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
40 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
41 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
42 Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods Completed NCT00180141 Phase 4 Elidel-Creme
43 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed NCT00179959 Phase 4 Sodium hypochlorite (bleach) baths;Mupirocin ointment;Water;Petrolatum Ointment
44 Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) Completed NCT00878670 Phase 4 EPOGAM 1000
45 Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study Completed NCT01064947 Phase 4 Retapamulin 1%
46 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
47 Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis. Completed NCT00689832 Phase 4 Tacrolimus 0.03%;Fluticasone 0.005%
48 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
49 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
50 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)

Search NIH Clinical Center for Dermatitis, Atopic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
Doxepin
Doxepin Hydrochloride
fluocinolone
Fluocinolone Acetonide
methdilazine
Methdilazine hydrochloride
Pimecrolimus
Tacrolimus
Trimeprazine
trimeprazine tartrate
Triprolidine
Triprolidine Hydrochloride
Zinc Oxide

Cochrane evidence based reviews: dermatitis, atopic

Genetic Tests for Dermatitis, Atopic

Genetic tests related to Dermatitis, Atopic:

# Genetic test Affiliating Genes
1 Dermatitis, Atopic, Susceptibility to, 1 28

Anatomical Context for Dermatitis, Atopic

Organs/tissues related to Dermatitis, Atopic:

FMA: Skin
MalaCards : Skin, T Cells, Breast, Pituitary, Bone Marrow, Neutrophil, Heart

Publications for Dermatitis, Atopic

Articles related to Dermatitis, Atopic:

(show top 50) (show all 28379)
# Title Authors PMID Year
1
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. 53 62 57
17441792 2007
2
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. 53 62 5
16550169 2006
3
A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. 53 62 57
11101848 2000
4
Linkage of atopic dermatitis to chromosomes 4q22, 3p24 and 3q21. 62 57
19517137 2009
5
Atopic dermatitis. 62 57
18385500 2008
6
Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. 62 57
17850181 2007
7
Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. 62 5
16815158 2006
8
Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. 62 57
12045207 2002
9
Linkage and association to candidate regions in Swedish atopic dermatitis families. 62 57
11511916 2001
10
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. 62 57
11279517 2001
11
Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. 62 57
11069631 2000
12
Mosaic atopic eczema cured by autotransplantation? 62 57
9752825 1998
13
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. 62 57
9643741 1998
14
The prevalence of childhood atopic eczema in a general population. 62 57
8277028 1994
15
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. 62 46
20673989 2010
16
Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. 5
17030239 2006
17
Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. 5
16444271 2006
18
Aetiology of asthma: lessons from lung transplantation. 57
8098790 1993
19
Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. 57
3059190 1988
20
Changes in the reported prevalence of childhood eczema since the 1939-45 war. 57
6150286 1984
21
The lines of Blaschko: a review and reconsideration: Observations of the cause of certain unusual linear conditions of the skin. 57
788770 1976
22
Sphingosylphosphorylcholine down-regulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. 53 62
20230798 2010
23
Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. 53 62
20483734 2010
24
[Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases]. 53 62
20525484 2010
25
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. 53 62
20466416 2010
26
Analysis of four prevalent filaggrin mutations (R501X, 2282del4, R2447X and S3247X) in Austrian and German patients with atopic dermatitis. 53 62
19874431 2010
27
Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. 53 62
20304960 2010
28
Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis. 53 62
20526842 2010
29
Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. 53 62
20335530 2010
30
Definition and characterization of an inhibitor for interleukin-31. 53 62
20335179 2010
31
The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. 53 62
20143171 2010
32
Sensing the outside world: TSLP regulates barrier immunity. 53 62
20300138 2010
33
[Atopic dermatitis - current insights into path physiology and management]. 53 62
20336617 2010
34
FLG mutations in ichthyosis vulgaris and atopic eczema: spectrum of mutations and population genetics. 53 62
19958351 2010
35
Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. 53 62
20444170 2010
36
Association of single nucleotide polymorphisms in the IL-12 (IL-12A and B) and IL-12 receptor (IL-12Rbeta1 and beta2) genes and gene-gene interactions with atopic dermatitis in Koreans. 53 62
20060272 2010
37
Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. 53 62
20107184 2010
38
Effects of transmembrane and juxtamembrane domains on proliferative ability of TSLP receptor. 53 62
20096461 2010
39
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. 53 62
20083663 2010
40
Genetics of allergic disease. 53 62
20176270 2010
41
Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of life. 53 62
19552791 2010
42
Chromosome 11q13.5 variant associated with childhood eczema: an effect supplementary to filaggrin mutations. 53 62
20109745 2010
43
Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. 53 62
19672094 2010
44
Association of single nucleotide polymorphism of interleukin-18 with atopic dermatitis. 53 62
19453784 2010
45
Human defensins and LL-37 in mucosal immunity. 53 62
19808939 2010
46
Thymic stromal lymphopoietin. 53 62
20146705 2010
47
What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies. 53 62
20082953 2010
48
Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. 53 62
20030614 2010
49
Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. 53 62
20136617 2010
50
Inflammatory cytokine tumor necrosis factor-alpha enhances nerve growth factor production in human keratinocytes, HaCaT cells. 53 62
19942804 2009

Variations for Dermatitis, Atopic

ClinVar genetic disease variations for Dermatitis, Atopic:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLG NM_002016.2(FLG):c.1501C>T (p.Arg501Ter) SNV Pathogenic
16319 rs61816761 GRCh37: 1:152285861-152285861
GRCh38: 1:152313385-152313385
2 KCNJ11 NM_000525.4(KCNJ11):c.185C>G (p.Thr62Arg) SNV Likely Pathogenic
373928 rs1057518775 GRCh37: 11:17409454-17409454
GRCh38: 11:17387907-17387907
3 CYP4F22 NM_173483.4(CYP4F22):c.1544G>T (p.Arg515Leu) SNV Uncertain Significance
523567 rs1425964436 GRCh37: 19:15662230-15662230
GRCh38: 19:15551419-15551419
4 CYP4F22 NM_173483.4(CYP4F22):c.1211T>C (p.Leu404Pro) SNV Uncertain Significance
523566 rs1555730246 GRCh37: 19:15658993-15658993
GRCh38: 19:15548182-15548182

Expression for Dermatitis, Atopic

Search GEO for disease gene expression data for Dermatitis, Atopic.

Pathways for Dermatitis, Atopic

Pathways related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 TSLP IL5 IL4 IL31 IL13 IFNG
2
Show member pathways
13.12 TSLP IL5 IL4 IL31 IL13 IFNG
3 11.83 IL5 IL4 IFNG
4 11.79 IL4 IL13 CCL22
5 11.73 IL5 IL4 IL13 IFNG
6 11.62 IL5 IL4 IL13 IFNG
7 11.56 IL5 IL4 IFNG
8
Show member pathways
11.54 IL5 IL4 IFNG
9 11.5 IL5 IL4 IL13
10 11.46 IL5 IL4 CCL17
11 11.46 TSLP IL5 IL4 IL13 IFNG
12
Show member pathways
11.44 IL5 IL4 IL13 IFNG
13 11.17 IFNG IL4 IL5
14 11.09 IL5 IL4 IL13 IFNG
15 10.97 IFNG IL13 IL4 IL5
16 10.86 CCL17 CCL22 IL13 IL4 IL5
17 10.86 TSLP IL5 IL4 IL13 IFNG
18 10.83 IL5 IL4 IL31 IL13 IFNG CCL22
19 10.75 IL4 IFNG
20 10.66 IL5 IL4 IL13

GO Terms for Dermatitis, Atopic

Biological processes related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.02 IL5 IL4 IL13 IFNG CCL22 CCL17
2 positive regulation of B cell proliferation GO:0030890 9.85 IL5 IL4 IL13
3 positive regulation of cellular respiration GO:1901857 9.73 IL4 IFNG
4 positive regulation of interleukin-10 production GO:0032733 9.73 IL13 IL4 TSLP
5 neuroinflammatory response GO:0150076 9.71 IL4 IFNG
6 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
7 microglial cell activation GO:0001774 9.43 IL4 IL13 IFNG
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.23 TSLP IL4 IL13 IFNG

Molecular functions related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.47 TSLP IL5 IL4 IL31 IL13 IFNG
2 cytokine receptor binding GO:0005126 9.26 IL4 IL31 IL13

Sources for Dermatitis, Atopic

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....